Phthalate draft report
This article was originally published in The Rose Sheet
Executive Summary
The National Toxicology Program Center for the Evaluation of Risks to Human Reproduction is requesting comments on the draft NTP brief on di-(2-ethylhexyl) phthalate. Comments are due July 5, according to a June 5 Federal Register 1notice. The draft brief evaluates the NTP's conclusions on the potential of DEHP to cause reproductive and developmental toxicity, and provides background information on the substance and findings of a CERHR expert panel. Among conclusions in the draft brief, NTP concurs with the expert panel that there is concern with effects on the development of the male reproductive tract for infants under one year of age. After the comment period and upon finalization, the NTP brief for DEHP will be included in the CERHR monograph for DEHP, center notes. NTP requested data on the ingredient last February, in preparation for a fall expert panel meeting (2"The Rose Sheet" Feb. 14, 2005, In Brief)...
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.